BACKGROUND:Fat gain after antiretroviral therapy (ART) occurs, and its association with protease inhibitors (PIs) is unclear. METHODS:Peripheral and central fat depots and lean mass were measured using standardized and centrally read abdominal CT scans and whole-body dual-energy absorptiometry scans over a 96-week period in human immunodeficiency virus (HIV)-infected treatment-naive participants. The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) in ACTG A5260s, a substudy of A5257. Within arm changes were assessed with signed-rank tests. The 96-week percentage changes in fat and lean mass in the 2 PI arms were not different, thus the PI arms were combined and compared to the RAL arm. Associations between baseline biomarkers and changes in body composition were assessed. All analyses used linear regression models. RESULTS:328 patients were randomized (90% male, 44% white non-Hispanic). The median age was 36 years, HIV-1 RNA 4.6 log10 copies/mL, and CD4 349 cells/μL. Overall, at week 96, increases in limb fat (13.4%), subcutaneous (19.9%) and visceral abdominal fat (25.8%), trunk fat (18%), and lean mass (1.8%) were apparent (P < .001 for changes within each arm). Changes for all fat and lean outcomes were not different between the PI arms or between the RAL and the combined PI arms. Higher baseline HIV-1 RNA levels were associated with greater gains in peripheral and central fat. CONCLUSIONS: In treatment-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat were found with RAL when compared with ATV/r or DRV/r over 96 weeks. CLINICAL TRIALS REGISTRATION: NCT00811954 and NCT00851799.
RCT Entities:
BACKGROUND: Fat gain after antiretroviral therapy (ART) occurs, and its association with protease inhibitors (PIs) is unclear. METHODS: Peripheral and central fat depots and lean mass were measured using standardized and centrally read abdominal CT scans and whole-body dual-energy absorptiometry scans over a 96-week period in human immunodeficiency virus (HIV)-infected treatment-naive participants. The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) in ACTG A5260s, a substudy of A5257. Within arm changes were assessed with signed-rank tests. The 96-week percentage changes in fat and lean mass in the 2 PI arms were not different, thus the PI arms were combined and compared to the RAL arm. Associations between baseline biomarkers and changes in body composition were assessed. All analyses used linear regression models. RESULTS: 328 patients were randomized (90% male, 44% white non-Hispanic). The median age was 36 years, HIV-1 RNA 4.6 log10 copies/mL, and CD4 349 cells/μL. Overall, at week 96, increases in limb fat (13.4%), subcutaneous (19.9%) and visceral abdominal fat (25.8%), trunk fat (18%), and lean mass (1.8%) were apparent (P < .001 for changes within each arm). Changes for all fat and lean outcomes were not different between the PI arms or between the RAL and the combined PI arms. Higher baseline HIV-1 RNA levels were associated with greater gains in peripheral and central fat. CONCLUSIONS: In treatment-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat were found with RAL when compared with ATV/r or DRV/r over 96 weeks. CLINICAL TRIALS REGISTRATION: NCT00811954 and NCT00851799.
Authors: S Duran; M Savès; B Spire; V Cailleton; A Sobel; P Carrieri; D Salmon; J P Moatti; C Leport Journal: AIDS Date: 2001-12-07 Impact factor: 4.177
Authors: Daniel Podzamczer; Elena Ferrer; Esteban Martínez; Luis Del Rio; Joaquín Rosales; Jordi Curto; Esteban Ribera; Pilar Barrufet; Josep M Llibre; Miquel Aranda Journal: AIDS Res Hum Retroviruses Date: 2009-06 Impact factor: 2.205
Authors: Adrian Curran; Esteban Martinez; Maria Saumoy; Luis del Rio; Manuel Crespo; Maria Larrousse; Daniel Podzamczer; Joaquin Burgos; Montse Lonca; Pere Domingo; Jose Maria Gatell; Esteban Ribera Journal: AIDS Date: 2012-02-20 Impact factor: 4.177
Authors: Michael P Dubé; Robert A Parker; Pablo Tebas; Steven K Grinspoon; Robert A Zackin; Gregory K Robbins; Ronenn Roubenoff; Robert W Shafer; David A Wininger; William A Meyer; Sally W Snyder; Kathleen Mulligan Journal: AIDS Date: 2005-11-04 Impact factor: 4.177
Authors: Grace A McComsey; Eric S Daar; MaryAnn O'Riordan; Ann C Collier; Lisa Kosmiski; Jorge L Santana; Carl J Fichtenbaum; Heidi Fink; Paul E Sax; Daniel E Libutti; Mariana Gerschenson Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Kristine M Erlandson; Suzanne P Fiorillo; Sandra Wagner Cardoso; Cynthia Riviere; Jorge Sanchez; James Hakim; Nagalingeswaran Kumarasamy; Sharlaa Badal-Faesen; Umesh Lalloo; Johnstone Kumwenda; Thomas B Campbell; Todd T Brown Journal: AIDS Res Hum Retroviruses Date: 2017-05-16 Impact factor: 2.205
Authors: Kellie L Hawkins; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown; Kristine M Erlandson Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: David R Bakal; Lara E Coelho; Paula M Luz; Jesse L Clark; Raquel B De Boni; Sandra W Cardoso; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Benedetta Bartali; Susan L Koletar; Kristine M Erlandson; Jordan E Lake; Michael T Yin; Kathy Melbourne; Belinda Ha; Todd T Brown Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Richard J Hodes; Felipe Sierra; Steven N Austad; Elissa Epel; Gretchen N Neigh; Kristine M Erlandson; Marissa J Schafer; Nathan K LeBrasseur; Christopher Wiley; Judith Campisi; Mary E Sehl; Rosario Scalia; Satoru Eguchi; Balakuntalam S Kasinath; Jeffrey B Halter; Harvey Jay Cohen; Wendy Demark-Wahnefried; Tim A Ahles; Nir Barzilai; Arti Hurria; Peter W Hunt Journal: Ann N Y Acad Sci Date: 2016-12 Impact factor: 5.691